[July 31, 2015]

Research and Markets: Global Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Report 2015 - Analysis of 31 Companies & 44 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/rg4q72/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• 4SC AG
• AbbVie Inc.
• Astllas Pharma Inc.
• Astex Pharmaceuticals, Inc.
• AstraZeneca Plc
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Cellular Biomedicine Group, Inc.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc
• ImmunoGen, Inc.
• Immunomedics, Inc.
• Infinity Pharmaceuticals, Inc.
• Innate Pharma SA
• Juno Therapeutics Inc.
• Karyopharm Therapeutics, Inc.
• Les Laboratoires Servier SAS (News - Alert)
• LFB S.A.
• MedImmune, LLC
• Millennium Pharmaceuticals, Inc.
• MorphoSys AG
• Neopharm Ltd.
• Novartis AG
• Ono Pharmaceutical Co., Ltd.
• Portola Pharmaceuticals, Inc.
• Sanofi
• SpectraMab GmbH
• TG Therapeutics, Inc.
• Threshold Pharmaceuticals, Inc.
  
  
  
  

Drug Profiles

• 4SC-202
• ACP-196
• afuresertib hydrochloride
• AGS-67E
• AT-7519
• AZD-6738
• BI-836826
• BMS-986016
• buparlisib hydrochloride
• CBM-C19.1
• CBM-C20.1
• CC-122
• Cell Therapy to Target (News - Alert) Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia
• cerdulatinib
• duvelisib
• evofosfamide
• FBTA-05
• GS-9901
• IMGN-529
• IMMU-114
• IPH-2201
• JCAR-014
• JCAR-015
• MEDI-551
• MOR-208
• moxetumomab pasudotox
• nivolumab
• obinutuzumab
• pilaralisib
• S-055746
• selinexor
• spebrutinib besylate
• TAK-659
• TGR-1202
• tisagenlecleucel-T

For more information visit http://www.researchandmarkets.com/research/rg4q72/refractory

View source version on businesswire.com: http://www.businesswire.com/news/home/20150731005405/en/

[ Back To TMCnet.com's Homepage ]